Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.

Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY, Stopa EG, Babich J, Fischman AJ.

Synapse. 1998 Jun;29(2):116-27.

PMID:
9593102
2.

Dopamine receptors and transporters in Parkinson's disease and schizophrenia.

Seeman P, Niznik HB.

FASEB J. 1990 Jul;4(10):2737-44. Review.

PMID:
2197154
3.

Iometopane: (123)I beta-CIT, dopascan injection, GPI 200, RTI 55.

[No authors listed]

Drugs R D. 2003;4(5):320-2. Review.

PMID:
12952503
4.

Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders.

Kugaya A, Fujita M, Innis RB.

Ann Nucl Med. 2000 Feb;14(1):1-9. Review.

PMID:
10770574
5.

[Functional neuroimaging in movement disorders].

Borbély K.

Orv Hetil. 2001 Oct 28;142(43):2347-55. Review. Hungarian.

PMID:
11760452
6.
7.

Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease.

Marek K, Jennings D, Seibyl J.

Adv Neurol. 2003;91:183-91. Review. No abstract available.

PMID:
12442677
8.

Dopamine receptors in Parkinson's disease: imaging studies.

Stoessl AJ, de la Fuente-Fernández R.

Adv Neurol. 2003;91:65-71. Review. No abstract available.

PMID:
12442664
9.

How useful is (123I) beta-CIT SPECT in the diagnosis of Parkinson's disease?

Bhidayasiri R.

Rev Neurol Dis. 2006 Winter;3(1):19-22. Review.

PMID:
16596082
10.

Radiopharmaceuticals for single-photon emission computed tomography brain imaging.

Kung HF, Kung MP, Choi SR.

Semin Nucl Med. 2003 Jan;33(1):2-13. Review.

PMID:
12605353
11.

Neuroinflammation in the living brain of Parkinson's disease.

Ouchi Y, Yagi S, Yokokura M, Sakamoto M.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S200-4. doi: 10.1016/S1353-8020(09)70814-4. Review.

PMID:
20082990
12.

Functional imaging of neurotransmitter systems in movement disorders.

Ilgin N.

Q J Nucl Med. 1998 Sep;42(3):179-92. Review.

PMID:
9796366
13.

Dopamine transporter: basic aspects and neuroimaging.

Piccini PP.

Mov Disord. 2003 Oct;18 Suppl 7:S3-8. Review.

PMID:
14531039
14.

Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.

Poewe W, Scherfler C.

Mov Disord. 2003 Oct;18 Suppl 7:S16-21. Review.

PMID:
14531041
15.

N-((E)-4-[18F]Fluorobut-2-en-1-yl)-2β-carbomethoxy-3β-(4'-fluorophenyl)nortropane.

Stehouwer JS, Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Jan 31 [updated 2011 Mar 31].

16.

Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.

Au WL, Adams JR, Troiano AR, Stoessl AJ.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):24-33. Epub 2004 Nov 2. Review.

PMID:
15790527
17.

PET evaluation of the dopamine system of the human brain.

Volkow ND, Fowler JS, Gatley SJ, Logan J, Wang GJ, Ding YS, Dewey S.

J Nucl Med. 1996 Jul;37(7):1242-56. Review.

18.

Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Kish SJ, Boileau I, Callaghan RC, Tong J.

Eur J Neurosci. 2017 Jan;45(1):58-66. doi: 10.1111/ejn.13363. Epub 2016 Sep 5. Review.

19.

Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact.

Catafau AM.

Nucl Med Commun. 2001 Oct;22(10):1059-60. Review. No abstract available.

PMID:
11567176
20.

[Nuclear neuroimaging of dopamine transporter in Parkinsonism--role in routine clinical practice].

Cohenpour M, Golan H.

Harefuah. 2007 Sep;146(9):698-702, 733. Review. Hebrew.

PMID:
17969308

Supplemental Content

Support Center